The Consistent Effectiveness and Safety of Macitentan Therapies Across Idiopathic and Congenital Heart Disease-Associated PulmonaryArterial Hypertension: A Single-Center Experience
Authors:
- Cihangir KaymazCKCihangir Kaymaz
- Seda TanyeriSTSeda Tanyeri
- Hacer Ceren TokgozHTHacer Ceren Tokgoz
- Ozgur Yasar AkbalOAOzgur Yasar Akbal
- Ali KaragozAKAli Karagoz
- Berhan KeskinBKBerhan Keskin
- Barkin KultursayBKBarkin Kultursay
- Aykun HakgorAHAykun Hakgor
- Seyhmus KulahciogluSKSeyhmus Kulahcioglu
- Zubeyde BayramZBZubeyde Bayram
- Suleyman Cagan EfeSESuleyman Cagan Efe
- Ibrahim Halil TanbogaITIbrahim Halil Tanboga
Open Access
- 1 October 2022
- journal article
- research article
- Published by Kare Publishing in The Anatolian Journal of Cardiology
- Vol. 26 (10) , 778-787
Abstract
Macitentan,pulmonary arterial hypertension,Eisenmenger syndrome,REVEAL-Lite 2,COMPERA,SPAHRKeywords
This publication has 37 references indexed in Scilit:
- Long-term results of treatment with bosentan in adult Eisenmenger’s syndrome patients with Down’s syndrome related to congenital heart diseaseBMC Cardiovascular Disorders, 2013
- Macitentan and Morbidity and Mortality in Pulmonary Arterial HypertensionNew England Journal of Medicine, 2013
- Therapy for pulmonary arterial hypertension due to congenital heart disease and Down's syndromeInternational Journal of Cardiology, 2013
- Slow Receptor Dissociation Kinetics Differentiate Macitentan from Other Endothelin Receptor Antagonists in Pulmonary Arterial Smooth Muscle CellsPLOS ONE, 2012
- Ambrisentan for Pulmonary Arterial Hypertension Due to Congenital Heart DiseaseThe American Journal of Cardiology, 2011
- Endothelin Receptor Antagonists are an Effective Long Term Treatment Option in Pulmonary Arterial Hypertension Associated with Congenital Heart Disease With or Without Trisomy 21Heart, Lung and Circulation, 2010
- Predicting Survival in Pulmonary Arterial HypertensionCirculation, 2010
- Improved Survival Among Patients With Eisenmenger Syndrome Receiving Advanced Therapy for Pulmonary Arterial HypertensionCirculation, 2010
- Effect of Bosentan on Exercise Capacity and Quality of Life in Adults With Pulmonary Arterial Hypertension Associated With Congenital Heart Disease With and Without Down's SyndromeThe American Journal of Cardiology, 2009
- Bosentan Therapy in Patients With Eisenmenger SyndromeCirculation, 2006